Abstract
Opicapone (OPC) proved to be effective in treating end-of-dose motor fluctuations (MF) in Parkinson's disease (PD) patients. The OPTIPARK study evaluated OPC 50 mg in a heterogeneous population of PD patients treated in real-world conditions. We evaluated the influence of baseline demographic characteristics on the response to OPC in PD patients with MF.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
